(Q46110144)

English

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

scientific article published on 7 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

phase III clinical trial

0 references

0 references

0 references

5

object named as

F Stephen Hodi

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

Reinhard Dummer

2

object named as

Reinhard Dummer

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

author name string

Jeffrey S Weber

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

Veerle de Pril

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

Celeste Lebbé

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

MDX010-20 Investigators

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

language of work or name

0 references

publication date

7 February 2013

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

119

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

1675-1682

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27969

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27969

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/23400564

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46110144&oldid=2093218006"